Ficha del valor · trimestre archivado
SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
13Tenedores rastreados
-4Δ titulares
17.49MAcciones mantenidas
$175.83MValor declarado
+1Nuevas posiciones
−5Cierres
Señales de momentum (gestores comparables):
amplitud de titulares -23.5% ·
flujo de acciones -18.0% ·
nuevas posiciones netas -20.0%
— fórmula
Distribución amplia — caída de acciones y menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
Participación a lo largo del tiempo
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
Quién lo tiene en cartera · Q3 2025
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (pasivo) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | The Vanguard Group ✦ (pasivo) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | The Vanguard Group ✦ (pasivo) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | The Vanguard Group ✦ (pasivo) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (pasivo) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | The Vanguard Group ✦ (pasivo) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (pasivo) | 2.90M | +31.9% | $29.10M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 1.59M | -29.3% | $15.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 1.59M | -29.3% | $15.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Geode Capital Management ✦ (pasivo) | 1.51M | +12.2% | $15.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Geode Capital Management ✦ (pasivo) | 1.51M | +12.2% | $15.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Goldman Sachs Group ✦ | 1.33M | — | $13.32M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Goldman Sachs Group ✦ | 1.33M | — | $13.32M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Fidelity (FMR) ✦ | 742.51K | -52.6% | $7.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 25 | Fidelity (FMR) ✦ | 742.51K | -52.6% | $7.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 33 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 34 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 35 | Two Sigma Investments ✦ | 72.18K | Nuevo | $725,379 | 0.0% | New | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 44 | D. E. Shaw & Co. ✦ | 34.22K | -40.4% | $343,901 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 45 | D. E. Shaw & Co. ✦ | 34.22K | -40.4% | $343,901 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 46 | T. Rowe Price ✦ | 33.79K | +23.4% | $340,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Two Sigma Investments | $725,379 | 0.0% |
Posición cerrada
| Adage Capital Partners | $30.15M | era 0.1% |
| Wellington Management | $25.01M | era 0.0% |
| Millennium Management | $15.32M | era 0.0% |
| Gotham Asset Management | $475,617 | era 0.0% |
| AQR Capital Management | $281,503 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 201 tenedores, 92.94M acciones, $730.00M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Frecuentemente cotituladas
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Procedencia: Participación a partir de posiciones en acciones ordinarias de 13F procesadas (universo rastreado, conjuntos comparables para cambios); filas de iniciados de los Formularios 3/4/5; participaciones de los Schedules 13D/13G; cada filing enlaza con su original en SEC EDGAR.
Período de reporte: Q3 2025 ·
Metodología ·
Obtener esto a través de la API